CytomX Therapeutics Announces CX-2051 Phase 1 Colorectal Cancer Expansion Data On Track For Q1 2026; Varseta-M Phase 1 Combination Study With Bevacizumab In Colorectal Cancer To Start In Q1 2026 With Initial Data Expected By H1 2027

- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 -

- Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 -

- Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 -

- Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th -

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced a business update and anticipated milestones for 2026.